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·The clinical and biochemical effects of two
combination oral contraceptive agents
K. E. SAPIRE G BERGER, .M.B. , J. S. MARITZ
Summary
: compa~is.on of the effects of two low-dose oral contracep-
ves on h~ld met~bolism was undertaken in an open-group·
comparative deSign stUdy at the Family Planning Clinic,
;roote Schuur Hospital, Cape Town. Sixty healthy women
g~ 18 - 35 years requesting oral contraception were allo-
~a e . ~Iternately to use a monophasic oral contraceptive
~ntalnlng 30 J.Lg ethinyloestradiol and 150 ",g desogestrel
fn a!:oelon, group .A), or a triphasic oral contraceptive contain-
Tg. - ~O J.Lg ethlny1oestradiol and 50 - 125 ",g levonorgestrel
( .."phaSIl, group B). The changes in the lipoprotein profile
: IClt~ by the two preparations differed significantly. Group
4 su Jeets had a mUch greater triglyceridaemic response
f 2,~%) than.gr~up B (14,6%) and had a significant increase
n hl~h-denslty hpoprotein cholesterol (HDL-C) and apolipo-
protein A-l (Apo·~l). In rou B, HDL-C decreased and
Apo-Al showed hUle cha~g/Non-HDL-C (NHDL-C) and
A~-B leVels hardly Changed in either group. The atherogenic
ratios, NHDL-C/HDL.C and Apo-B/Apo-Al were higher in
group B.
This study confi",:,ed a significant difference in the response
f-f plasma hp~prote,"s to the two oral contraceptive prepara-
Ions. The eVidence Suggests that the desogestrel-containing
:al contraceptive eliCit, a less atherogenic lipoprotein profile
an does the levonorgeatrel_containing preparation. Although
~n,upported by direct Clinical evidence that changes in the
hpoprotein p~ttern indUCed by oral contraceptives cause
athero~C:lerosls, these effects should be considered when
rr~cnblng oral contraceptives for women who have risk
ac ora for cardiovascUlar disease.
S Atr Med J 1991; 79: 376-379.
The adverse cardiovascular effects of oral contraceptives have
been well.documented. I•2 These are probably mediated through
changes. In 6 the plasma lipoprotein profrle/-s in the blood
coagulatlon and fibrinolytic systems,7 and through effects on
blood pressures and Carbohydrate metabolism.9 The risk of
~oronary artery disease is exacerbated by smoking, especially
m women over the age of 35 ID
S 'd . years.
term ~Induced changes in plasma lipoprotein transport
have rec~Ived considerable attention due to the established
role of lipoprote~s in atherogenesis and as a risk factor for
c~r~nary artery dIsease. II Oral contraceptive preparations con-
tammg. 50 J.Lg ethinyloestradiol are associated with a signifi-
c~t1y Increased risk of thrombo-embolic events, hypertension,
weIght gain and with hyperinsulinism and impaired glucose
tolerance. 12 Oestrogens also enhance plasma triglyceride and
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high-density lipoprotein cholesterol (HDL-C) levels, more
specifically the HDL2 subfraction; the latter effect is seen as
beneficial. Low-dose preparations containing 30 - 35 p.g ethinyl-
oestradiol are associated with a significant reduction in the
adverse oestrogenic effects 13,14 and may even be beneficial in
certain categories of women as far as coronary artery disease is
concerned. IS
It has become apparent that the progestogen in oral contra-
ceptives potentiates some of the adverse actions of oestrogens
and may counteract the beneficial effects. 16 Progestogens have
androgenic as well as progestational properties and, in addition,
may possess anti-androgenic and anti-oestrogenic actions. The
effects of any combined oral contraceptive preparation will
therefore depend on the nature and relative biological activity·
of the oestrogen and progestogen used, as well as the absolute
dose, and the characteristics of the recipient. 17 In this connec-
tion, the increased risk of coronary artery disease associated
with oral contraceptive use is mainly, although not entirely,
confined to women over the age of 35 years, and especially
current smokers. ID In developing new oral contraceptives
attention has been directed towards minimising risks by dose
reduction, ancj. by modification of the progestogen component,
while maintaining contraceptive efficacy. .
In this study a monophasic oral contraceptive preparation
(A) (Marvelon; Donmed) containing 30 J.Lg ethinyloestradiol
and 150 J.Lg desogestrel was compared with a triphasic prepara-
tion (B) (Triphasil; Akromed) containing ethinyloestradiol
30 - 40 J.Lg and levonorgestrel 50 - 125 J.Lg in two groups of
women. Both preparations contain low-dose ethinyloestradiol
and differ primarily in the amount and nature of the pro-
gestogen.
Subjects and methods
This was an open group-comparative study involving 62 healthy
women who requested oral contraceptives, and gave informed
consent for this clinical study. They were alternately allocated
to group A (the monophasic preparation) or group B. (the
triphasic preparation), except that current cigarette smokers (5
in each group) were allocated to each group alternately in
equal numbers. ODly the research sister knew which oral
contraceptive constituted group A or B until the data were
computerised. .
The study period lasted 4 months and included 2 visits in
the pre-treatment month and 3 follow-up visits between day
18 and day 21 of the treatment cycles 1, 2 and 3. At each visit,
blood was collected after a l2-hour fast. Tablets were checked
at each visit to ensure compliance, and subjects were reminded
to continue on·their normal diet and other lifestyles.
All women selected were between 18 years and 35 years of
age, were normolipidaemic, and were healthy on routine ques-
tioning and clinical examination. None took any hormonal
preparation or other medication in the 2 months before inclu-
sion in the study or during the trial itself, except for the'
prescribed oral contraceptive. Standard contraindications to
oral contraceptives were applied. In addition, women with an
intake of more than 2 glasses of alcohol per day and also those
weighing over 80 kg or following a diet, and those who ·were
less than 3 months postpartum or post-abortion, were excluded.
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TABLE I. PRETREATMENT CLINICAL AND BIOCHEMICAL FEATURES OF GROUPS A AND B (MEAN±SD)
Group (N) Age (yrs) BMI CHOL HDL-C" NHDL-C Triglycerides Apo-A1 Apo-B
A (30) 22,6 ± 3,10 23,2 ± 3,2 4,43 ± 0,64 1,59 ± 0,28 2,84 ± 0,65 0,64 ± 0,23 149 ± 22,0 80,2 ± 18,0
B (30) 22,0 ± 4,40 22,0 ± 2,9 4,30 ± 0,70 1,46 ± 0,24 2,84 ± 0,70 0,69 ± 0,18 141 ± 22,8 78,2 ± 22,6
Upid and apolipoprotein values represent the mean of the first 2 visits.
Fig. 1. Changes in plasma lipid and apolipoprotein levels in
response to oral contraceptives A and B.
TABLE 11. CHANGES IN LIPOPROTEIN COMPOSITION AND
LIPOPROTEIN RATIOS IN RESPONSE TO ORAL CONTRACEP-



























•• - Significant difference between groups (P < 0,05).
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6,9% fall in HDL-C without significantly affecting Apo-Al
levels. The responses of the two groups were significantly
different from one another at P = 0,001 and P = 0,003 for
HDL-C and Apo-Al, respectively. Both preparations A and B
elicited an increase in plasma triglyceride levels. Group A
subjects showed a 42,4% rise whereas triglyceride levels rose
by 14,6% in group B subjects. The triglyceridaemic responses
of the two groups differed significantly (P = 0,0003) from one
another.
In contrast to the striking changes in HDL and triglyceride
concentrations, total plasma cholesterol and NHDL-C levels
altered relatively little. Both groups showed a small, non-
significant fall in NHDL-C concentration whereas group A
showed a slight rise (2,1%) and group B a slight fall (-3,8%) in
total plasma cholesterol, presumably reflecting changes in the
HDL-C values. Apo-B rose by 3,7% and 8,1% in groups A and
B, respectively, but these changes also did not achieve statistical
. significance, and the two groups did not differ significantly
from one another.
The ratio of NHDL-C/HDL-C and Apo-B/Apo-Al may
be taken as a reflection of atherogenic potential. These ratios
were reduced by 8,7% (P = 0,04) and 10,4% (non-significant)
Laboratory investigations
Blood was taken without venesta~is, placed in tubes contain-
ing ethylenediarninetetra-acetic acid and centrifuged within 1
hour at 4° to separate cells from plasma. Lipid assay was
performed immediately or within 4 days. Apolipoprotein assay
was batched and carried out on samples stored at -70°C for
less than 3 months.
Total plasma cholesterol was estimated enzymatically using
a commercial kit (Boehringer-Mannheim CHOD-PAP High
Performance kit) and triglyceride was similarly determined
(Clinical Colorimetric Enzymatic Method, Carlo Erba, Milan).
HDL-C was measured after precipitation of the low-density
lipoprotein (LDL), and very low-density lipoprotein (VLDL)
by means of heparin-manganese according to the Lipid
Research Clinics protocol. I8 VLDL-C plus LDL-C levels
were estimated by subtracting HDL-C from total plasma
cholesterol. This product, termed non-HDL-cholesterol
(NHDL-C), represents the cholesterol associated with the two
atherogenic apo B-containing fractions. Apolipoprotein A-I
(Apo-Al) was determined by rate nephelometry on a Beckman
ICS system according to the method of Weinstock er al. 19 and
Apo-B by an immuno-electrophoretic (rocket) procedure.20
Results
The two groups were similar in age, body mass index, as well
as in dietary, smoking and alcohol consumption habits. The
basal lipid and apolipoprotein values of the two groups were
comparable (Table I).
Statistical analysis
Within-group comparisons of basal values with levels
achieved in the course of oral contraceptive therapy were made
by a procedure that is essentially a paired test, with allowance
being made for the co-variates age and smoking. Between-
group comparisons were made by two sample tests, that is
ANOVA, again with allowance for co-variates. The statistical
methods were implemented by means of the general linear
model procedure of Statistical Analysis System.21 All ANOVA
and regression procedures were performed on actual observed
changes. In some summaries percentage change values are
shown so as to facilitate interpretation. One patient from each
of the two groups dropped out of the trial after the 4th visit
for personal reasons. They were omitted from the statistical
analysis, which was thus performed on 30 individuals in each
group.
The percentage change· in plasma lipid and apolipoprotein
levels in the two groups is illustrated in Fig. 1. The effects of
the two oral contraceptives differed strikingly in the direction
of the HDL fraction change as well as in the extent of the
hypertriglyceridaemic response.
Preparation A elicited a significant increase in both HDL-C
(7,9%) and Apo-Al (13%) whereas preparation B caused a
